{
    "relation": [
        [
            "",
            "Linagliptin",
            "Glimepiride"
        ],
        [
            "Description",
            "Patients randomized to receive Linagliptin 5mg and metformin",
            "Patients randomized to receive Glimepiride 1-4mg and metformin"
        ]
    ],
    "pageTitle": "Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00622284?sect=Xj015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988065.26/warc/CC-MAIN-20150728002308-00194-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 860206367,
    "recordOffset": 860192489,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details There were in total 1560 patients randomised in the study. Of these, 1 patient was not treated. The remaining 8 patients not accounted for in the treated set were removed from all study analyses (explained in trial report) due to major good-clinical-practice violations at the site, and the inability to verify the validity of any patient level data. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Placebo identical to BI 1356 5mg Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg Drug: BI 1356 Drug: Glimepiride Interventions:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Linagliptin \u00a0 \u00a0 Glimepiride \u00a0 STARTED \u00a0 \u00a0 776 [1] \u00a0 775 [2] COMPLETED \u00a0 \u00a0 587 [3] \u00a0 604 [3] NOT COMPLETED \u00a0 \u00a0 189 \u00a0 \u00a0 171 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 45 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 15 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 61 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 90 \u00a0 Protocol Violation \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 12 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}